Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses [Yahoo! Finance]
Pharvaris N.V. - Ordinary Shares (PHVS)
Company Research
Source: Yahoo! Finance
antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at two upcoming congresses: the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA) , to be held from March 14-16, 2024, in Milan, Italy, and the 2024 HAE International (HAEi) Regional Conference Americas , to be held from March 15-17, 2024, in Panama City, Panama. Details of the presentations are as follows: 3rd ITACA National Congress , Milan, Italy, March 14-16, 2024. Title: Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks Presenter: Mauro Cancian, M.D., Ph.D. Format: Poster Presentation Date, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT) Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment
Show less
Read more
Impact Snapshot
Event Time:
PHVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHVS alerts
High impacting Pharvaris N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PHVS
News
- Pharvaris (NASDAQ: PHVS) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $34.00 price target on the stock.MarketBeat
- Pharvaris (NASDAQ: PHVS) had its price target lowered by analysts at Morgan Stanley from $35.00 to $34.00. They now have an "overweight" rating on the stock.MarketBeat
- Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]Yahoo! Finance
- Pharvaris (NASDAQ: PHVS) had its price target raised by analysts at JMP Securities from $49.00 to $50.00. They now have a "market outperform" rating on the stock.MarketBeat
- Pharvaris (NASDAQ: PHVS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $35.00 price target on the stock.MarketBeat
PHVS
Earnings
- 5/8/23 - Beat
PHVS
Sec Filings
- 4/23/24 - Form 144
- 4/15/24 - Form 144
- 4/12/24 - Form F-3ASR
- PHVS's page on the SEC website